<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01534143</url>
  </required_header>
  <id_info>
    <org_study_id>2011-151</org_study_id>
    <secondary_id>NCI-2012-00120</secondary_id>
    <nct_id>NCT01534143</nct_id>
  </id_info>
  <brief_title>High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant</brief_title>
  <official_title>A Pilot Study Using High Dose Busulfan and Bortezomib as Part of Allogeneic Transplant Conditioning Regimen for High Risk Multiple Myeloma Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot phase II trial studies how well giving high dose busulfan together with bortezomib
      works in treating patients with high risk multiple myeloma undergoing stem cell transplant.
      Drugs used in chemotherapy, such as busulfan, work in different ways to stop the growth of
      cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may
      stop the growth of cancer cells by blocking some of the enzymes needed for cells growth.
      Giving busulfan together with bortezomib before a stem cell transplant may kill more cancer
      cells
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine time to engraftment absolute neutrophil count (&gt; 0.5 x 10^9/L for 3
      consecutive days), and platelet (&gt; 20X 109^/L for 3 consecutive days).

      2. Incidence and severity of acute graft-versus-host disease (GVHD) using fludarabine
      (fludarabine phosphate) / busulfan / bortezomib preparative regimen and triple immune
      suppression with tacrolimus, sirolimus and Thymoglobulin (anti-thymocyte globulin).

      3. To determine the safety related to this combination in the first six months post
      transplant, specifically, treatment related mortality and grade III and IV non hematologic
      toxicities, based on Common Terminology Criteria for Adverse Events (CTCAE) version 4 (v4).

      SECONDARY OBJECTIVES:

      I. Incidence of myeloma progression in this high risk group of patients.

      II. Incidence of transplant related mortality and morbidity.

      III. Incidence of thrombotic thrombocytopenic purpura (TTP) and sinusoidal obstructive
      syndrome (SOS).

      IV. Incidence and severity of chronic GVHD.

      V. Incidence of opportunistic infections including cytomegalovirus (CMV), herpes simplex
      virus (HSV), and Epstein-Barr virus (EBV) reactivation.

      I. Overall and progression free survival (PFS) at Day 100, 6 months, 1 &amp; 2 years post
      transplant.

      VII. To determine recovery of T-cell, B cell, and natural killer (NK) cell phenotypes post
      transplant.

      OUTLINE:

      CONDITIONING REGIMEN: Patients receive fludarabine phosphate intravenously (IV) on days -7 to
      -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.

      GVHD PROPHYLAXIS: Patients receive anti-thymocyte globulin IV on days -3 to -1, sirolimus
      orally (PO) on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic hematopoietic
      stem cell transplantation (HSCT) on day 0.

      After completion of study treatment, patients are followed up for up to 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Data was not collected, because funding was unavailable to continue study.
  </why_stopped>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of Acute GVHD Using Fludarabine Phosphate / Busulfan / Bortezomib Preparative Regimen and Triple Immune Suppression With Tacrolimus, Sirolimus and Anti-thymocyte Globulin</measure>
    <time_frame>First 6 months post-transplant</time_frame>
    <description>Graded using the Glucksberg scale. Proportions and confidence intervals will be estimated. Estimated using binary proportion estimates as well as competing risk method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Platelet Absolute Neutrophil Recovery (Engraftment)</measure>
    <time_frame>First 6 months post-transplant</time_frame>
    <description>Estimated using Kaplan-Meier method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Related Mortality Defined as Death in Continuous or Complete Remission</measure>
    <time_frame>From the date of transplant to the date of death, assessed up to 6 months post transplant</time_frame>
    <description>Based on National Cancer Institute (NCI) CTCAE version 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade III and IV Non Hematologic Toxicities</measure>
    <time_frame>First 6 months post transplant</time_frame>
    <description>Based on NCI CTCAE version 4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Myeloma Progression</measure>
    <time_frame>Time to the first observation of disease progression/relapse post transplant, assessed up to 2 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Transplant Related Mortality and Morbidity</measure>
    <time_frame>Up to 2 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of TTP</measure>
    <time_frame>Up to 2 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SOS</measure>
    <time_frame>Up to 2 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Chronic GVHD</measure>
    <time_frame>Up to 2 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Opportunistic Infections Including CMV, HSV, and EBV Reactivation</measure>
    <time_frame>Weekly to day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 2 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From the day of transplant to progression, death, or last contact, assessed up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery of T-cell, B Cell and NK Cell Phenotypes</measure>
    <time_frame>Days 30, 60, 90, and at 6 months after transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Refractory Multiple Myeloma</condition>
  <condition>Stage I Multiple Myeloma</condition>
  <condition>Stage II Multiple Myeloma</condition>
  <condition>Stage III Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy, enzyme inhibitor)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.
GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy, enzyme inhibitor)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, enzyme inhibitor)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (chemotherapy, enzyme inhibitor)</arm_group_label>
    <other_name>AY 22989</other_name>
    <other_name>Rapamune</other_name>
    <other_name>rapamycin</other_name>
    <other_name>SLM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, enzyme inhibitor)</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>lymphocyte immune globulin</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, enzyme inhibitor)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, enzyme inhibitor)</arm_group_label>
    <other_name>BSF</other_name>
    <other_name>BU</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeloleukon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, enzyme inhibitor)</arm_group_label>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>VELCADE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo allogeneic HSCT</description>
    <arm_group_label>Treatment (chemotherapy, enzyme inhibitor)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy, enzyme inhibitor)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide informed consent

          -  Karnofsky Performance Status (KPS) &gt;= 70

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2

          -  Availability of a suitable allogeneic hematopoietic stem cell donor; minimum of human
             leukocyte antigen (HLA) 7/8 matched related or unrelated donor

          -  High risk multiple myeloma with poor prognostic features based on having one or more
             of the following criteria:

          -  Progressive disease after autologous transplant. No less than 3 months post auto
             transplant

          -  Progressive or stable disease after induction chemotherapy using the most potent
             myeloma agents Lenalidomide and/or Bortezomib

          -  Patients with high risk cytogenetic abnormalities documented on conventional
             cytogenetics or fluorescence in situ hybridization (FISH) (hypodiploidy, t(4:14),
             t(14:16) chromosome translocation, p53 and or complex cytogenetics) additionally,
             chromosome 13 deletion by standard cytogenetics

          -  Negative beta-human chorionic gonadotropin (β-HCG) pregnancy test for women, as well
             as implementation of birth control for men and women

        Exclusion Criteria:

          -  Patients with prior allogeneic transplant, or more than one prior autologous
             transplant for any medical reason

          -  Prior treatment with busulfan or gemtuzumab (Mylotarg ®) for any reason

          -  Patient with history of allergy to boron, mannitol, or bortezomib

          -  Creatinine clearance (CrCl) =&lt; 50 ml/min

          -  Ejection Fraction &lt; 50%

          -  Diffusion capacity of carbon monoxide (DLCO) &lt; 50% predicted

          -  Forced expiratory volume in 1 second (FEV1) &lt; 50% predicted

          -  Forced vital capacity (FVC) &lt; 50% predicted

          -  Patients with uncontrolled arrhythmia or uncontrolled heart disease at the screening
             time; patients with coronary heart disease (recent myocardial infarctions, angina,
             cardiac stent, or bypass surgery in the last 6 months) need to be cleared with a
             stress echo or nuclear myocardial perfusion stress test, and cardiology consult; all
             other cardiac history will be at the discretion of the principal investigator

          -  Liver enzymes &gt; 3 times upper limit normal

          -  Bilirubin &gt; 2 mg/dl (except Gilbert's disease)

          -  International normalized ratio (INR) &gt; 2

          -  Any previous history of liver failure, hepatitis, or cirrhosis

          -  Systemic Amyloidosis Known history of hepatitis B, C, human immunodeficiency virus
             (HIV) or any current uncontrolled infection

          -  Grade &gt; I neuropathy

          -  Women who are pregnant or lactating

          -  Current or history of alcohol or drug abuse

          -  Use of other investigational agents within 30 days of enrollment to this study

          -  Any patient with ascites

          -  Any patient on home oxygen

          -  Any clinical findings on history or physical exam which would in the opinion of the
             treating physician or principal investigator preclude the patient from participating
             in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zaid Al-Kadhimi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2012</study_first_submitted>
  <study_first_submitted_qc>February 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2012</study_first_posted>
  <results_first_submitted>October 22, 2013</results_first_submitted>
  <results_first_submitted_qc>October 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 16, 2013</results_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Zaid Al-Kadhimi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Cancer center clinic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Chemotherapy, Enzyme Inhibitor)</title>
          <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.
GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0.
anti-thymocyte globulin : Given IV
pharmacological study : Correlative studies
fludarabine phosphate : Given IV
busulfan : Given IV
bortezomib : Given IV
allogeneic hematopoietic stem cell transplantation : Undergo allogeneic HSCT
tacrolimus : Given IV
laboratory biomarker analysis : Correlative studies
sirolimus : Given PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Chemotherapy, Enzyme Inhibitor)</title>
          <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.
GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0.
anti-thymocyte globulin : Given IV
pharmacological study : Correlative studies
fludarabine phosphate : Given IV
busulfan : Given IV
bortezomib : Given IV
allogeneic hematopoietic stem cell transplantation : Undergo allogeneic HSCT
tacrolimus : Given IV
laboratory biomarker analysis : Correlative studies
sirolimus : Given PO</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence and Severity of Acute GVHD Using Fludarabine Phosphate / Busulfan / Bortezomib Preparative Regimen and Triple Immune Suppression With Tacrolimus, Sirolimus and Anti-thymocyte Globulin</title>
        <description>Graded using the Glucksberg scale. Proportions and confidence intervals will be estimated. Estimated using binary proportion estimates as well as competing risk method.</description>
        <time_frame>First 6 months post-transplant</time_frame>
        <population>Data was not collected, because funding was unavailable to continue study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Enzyme Inhibitor)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.
GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0.
anti-thymocyte globulin : Given IV
pharmacological study : Correlative studies
fludarabine phosphate : Given IV
busulfan : Given IV
bortezomib : Given IV
allogeneic hematopoietic stem cell transplantation : Undergo allogeneic HSCT
tacrolimus : Given IV
laboratory biomarker analysis : Correlative studies
sirolimus : Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence and Severity of Acute GVHD Using Fludarabine Phosphate / Busulfan / Bortezomib Preparative Regimen and Triple Immune Suppression With Tacrolimus, Sirolimus and Anti-thymocyte Globulin</title>
          <description>Graded using the Glucksberg scale. Proportions and confidence intervals will be estimated. Estimated using binary proportion estimates as well as competing risk method.</description>
          <population>Data was not collected, because funding was unavailable to continue study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Platelet Absolute Neutrophil Recovery (Engraftment)</title>
        <description>Estimated using Kaplan-Meier method.</description>
        <time_frame>First 6 months post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Enzyme Inhibitor)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.
GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0.
anti-thymocyte globulin : Given IV
pharmacological study : Correlative studies
fludarabine phosphate : Given IV
busulfan : Given IV
bortezomib : Given IV
allogeneic hematopoietic stem cell transplantation : Undergo allogeneic HSCT
tacrolimus : Given IV
laboratory biomarker analysis : Correlative studies
sirolimus : Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Platelet Absolute Neutrophil Recovery (Engraftment)</title>
          <description>Estimated using Kaplan-Meier method.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment Related Mortality Defined as Death in Continuous or Complete Remission</title>
        <description>Based on National Cancer Institute (NCI) CTCAE version 4.</description>
        <time_frame>From the date of transplant to the date of death, assessed up to 6 months post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Enzyme Inhibitor)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.
GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0.
anti-thymocyte globulin : Given IV
pharmacological study : Correlative studies
fludarabine phosphate : Given IV
busulfan : Given IV
bortezomib : Given IV
allogeneic hematopoietic stem cell transplantation : Undergo allogeneic HSCT
tacrolimus : Given IV
laboratory biomarker analysis : Correlative studies
sirolimus : Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Related Mortality Defined as Death in Continuous or Complete Remission</title>
          <description>Based on National Cancer Institute (NCI) CTCAE version 4.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Grade III and IV Non Hematologic Toxicities</title>
        <description>Based on NCI CTCAE version 4.</description>
        <time_frame>First 6 months post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Enzyme Inhibitor)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.
GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0.
anti-thymocyte globulin : Given IV
pharmacological study : Correlative studies
fludarabine phosphate : Given IV
busulfan : Given IV
bortezomib : Given IV
allogeneic hematopoietic stem cell transplantation : Undergo allogeneic HSCT
tacrolimus : Given IV
laboratory biomarker analysis : Correlative studies
sirolimus : Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Grade III and IV Non Hematologic Toxicities</title>
          <description>Based on NCI CTCAE version 4.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Myeloma Progression</title>
        <time_frame>Time to the first observation of disease progression/relapse post transplant, assessed up to 2 years post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Enzyme Inhibitor)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.
GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0.
anti-thymocyte globulin : Given IV
pharmacological study : Correlative studies
fludarabine phosphate : Given IV
busulfan : Given IV
bortezomib : Given IV
allogeneic hematopoietic stem cell transplantation : Undergo allogeneic HSCT
tacrolimus : Given IV
laboratory biomarker analysis : Correlative studies
sirolimus : Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Myeloma Progression</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Transplant Related Mortality and Morbidity</title>
        <time_frame>Up to 2 years post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Enzyme Inhibitor)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.
GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0.
anti-thymocyte globulin : Given IV
pharmacological study : Correlative studies
fludarabine phosphate : Given IV
busulfan : Given IV
bortezomib : Given IV
allogeneic hematopoietic stem cell transplantation : Undergo allogeneic HSCT
tacrolimus : Given IV
laboratory biomarker analysis : Correlative studies
sirolimus : Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Transplant Related Mortality and Morbidity</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of TTP</title>
        <time_frame>Up to 2 years post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Enzyme Inhibitor)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.
GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0.
anti-thymocyte globulin : Given IV
pharmacological study : Correlative studies
fludarabine phosphate : Given IV
busulfan : Given IV
bortezomib : Given IV
allogeneic hematopoietic stem cell transplantation : Undergo allogeneic HSCT
tacrolimus : Given IV
laboratory biomarker analysis : Correlative studies
sirolimus : Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of TTP</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of SOS</title>
        <time_frame>Up to 2 years post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Enzyme Inhibitor)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.
GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0.
anti-thymocyte globulin : Given IV
pharmacological study : Correlative studies
fludarabine phosphate : Given IV
busulfan : Given IV
bortezomib : Given IV
allogeneic hematopoietic stem cell transplantation : Undergo allogeneic HSCT
tacrolimus : Given IV
laboratory biomarker analysis : Correlative studies
sirolimus : Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of SOS</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence and Severity of Chronic GVHD</title>
        <time_frame>Up to 2 years post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Enzyme Inhibitor)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.
GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0.
anti-thymocyte globulin : Given IV
pharmacological study : Correlative studies
fludarabine phosphate : Given IV
busulfan : Given IV
bortezomib : Given IV
allogeneic hematopoietic stem cell transplantation : Undergo allogeneic HSCT
tacrolimus : Given IV
laboratory biomarker analysis : Correlative studies
sirolimus : Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence and Severity of Chronic GVHD</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Opportunistic Infections Including CMV, HSV, and EBV Reactivation</title>
        <time_frame>Weekly to day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Enzyme Inhibitor)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.
GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0.
anti-thymocyte globulin : Given IV
pharmacological study : Correlative studies
fludarabine phosphate : Given IV
busulfan : Given IV
bortezomib : Given IV
allogeneic hematopoietic stem cell transplantation : Undergo allogeneic HSCT
tacrolimus : Given IV
laboratory biomarker analysis : Correlative studies
sirolimus : Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Opportunistic Infections Including CMV, HSV, and EBV Reactivation</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>Up to 2 years post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Enzyme Inhibitor)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.
GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0.
anti-thymocyte globulin : Given IV
pharmacological study : Correlative studies
fludarabine phosphate : Given IV
busulfan : Given IV
bortezomib : Given IV
allogeneic hematopoietic stem cell transplantation : Undergo allogeneic HSCT
tacrolimus : Given IV
laboratory biomarker analysis : Correlative studies
sirolimus : Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <time_frame>From the day of transplant to progression, death, or last contact, assessed up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Enzyme Inhibitor)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.
GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0.
anti-thymocyte globulin : Given IV
pharmacological study : Correlative studies
fludarabine phosphate : Given IV
busulfan : Given IV
bortezomib : Given IV
allogeneic hematopoietic stem cell transplantation : Undergo allogeneic HSCT
tacrolimus : Given IV
laboratory biomarker analysis : Correlative studies
sirolimus : Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recovery of T-cell, B Cell and NK Cell Phenotypes</title>
        <time_frame>Days 30, 60, 90, and at 6 months after transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Enzyme Inhibitor)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.
GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0.
anti-thymocyte globulin : Given IV
pharmacological study : Correlative studies
fludarabine phosphate : Given IV
busulfan : Given IV
bortezomib : Given IV
allogeneic hematopoietic stem cell transplantation : Undergo allogeneic HSCT
tacrolimus : Given IV
laboratory biomarker analysis : Correlative studies
sirolimus : Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Recovery of T-cell, B Cell and NK Cell Phenotypes</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Chemotherapy, Enzyme Inhibitor)</title>
          <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.
GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0.
anti-thymocyte globulin : Given IV
pharmacological study : Correlative studies
fludarabine phosphate : Given IV
busulfan : Given IV
bortezomib : Given IV
allogeneic hematopoietic stem cell transplantation : Undergo allogeneic HSCT
tacrolimus : Given IV
laboratory biomarker analysis : Correlative studies
sirolimus : Given PO</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Staphylococcus bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>CMV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Data was not collected, because funding was unavailable to continue study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Zaid Al-Kahdimi, M.D.</name_or_title>
      <organization>Barbara Ann Karmanos Cancer Institute</organization>
      <phone>(313) 576-8022</phone>
      <email>zalkadh@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

